OAM
VNDA icon

Oberweis Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Oberweis Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,700
Closed -$163K – 249
2017
Q4 		$163K Buy
10,700
+100
+0.9% +$1.48K 0.04% 226
2017
Q3 		$190K Hold
10,600
– – 0.05% 155
2017
Q2 		$173K Hold
10,600
– – 0.05% 136
2017
Q1 		$148K Buy
+10,600
New +$151K 0.04% 137

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Oberweis Asset Management's VNDA Position: Q1 2018 in Review

Oberweis Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 10,700 shares — an estimated $163K sold.

Oberweis Asset Management first reported a position in VNDA in Q1 2017 and held it in 4 quarters. The position peaked at $190K in Q3 2017. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

  • Oberweis Asset Management reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Oberweis Asset Management sold 10,700 Vanda Pharmaceuticals shares in Q1 2018, an estimated $163K.
  • Oberweis Asset Management first reported a position in Vanda Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Oberweis Asset Management's Vanda Pharmaceuticals position peaked at $190K in Q3 2017.
  • 131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on Oberweis Asset Management's 13F filing for Q1 2018, filed 15 May 2018.